Skip to main content

What is Known About the Antiviral Agents Active Against Bovine Viral Diarrhea Virus (BVDV)?

Buy Article:

$63.00 plus tax (Refund Policy)

Viruses belonging to the Flaviviridae family cause clinically significant diseases in humans and animals. This family includes three genera: Pestivirus [including bovine viral diarrhea virus (BVDV)], Flavivirus [including yellow fever virus (YFV), dengue virus, and West Nile virus (WNV)], and Hepacivirus [including hepatitis C virus (HCV)].

BVDV is responsible for major losses in cattle, causing a range of clinical manifestations, and is also a problematic contaminant in the laboratory. Noncytopathic BVDV infection can remain unnoticed and infect laboratory cell lines through its presence in contaminated bovine serum used in cell culture.

BVDV is considered to be a valuable surrogate virus model for identifying and characterizing antiviral agents to be used against HCV. In some aspects of viral replication, BVDV is more advantageous than the currently used HCV replicon systems.

In this review, we report the design, synthesis, and activity against BVDV of a series of compounds assayed until now.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Antiviral agents; BVDV; HCV; Non-nucleosidic compounds; Nucleosidic compounds; Structure-activity relationship

Document Type: Research Article

Affiliations: Catedra de Quimica Medicinal, Facultad de Farmacia y Bioquimica, Universidad de Buenos Aires, Junin 956 (1113), Buenos Aires, Argentina.

Publication date: 2010-09-01

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more